【摘要】 目的 探讨甲磺酸奥希替尼片（以下简称“奥希替尼”）致心力衰竭的临床特点及作用机制，为临床用药提供参考。方法 分析1例59岁肺腺癌患者服用奥希替尼后出现心力衰竭，采用Naranjo’s（诺氏）评分及结合相关文献，探讨可能致心衰的药物、发生原因及防治措施。结果 患者发生的心力衰竭很有可能与奥希替尼有关，停药并积极抗心衰治疗后，患者心功能基本恢复。结论 奥希替尼引起心力衰竭相对较少，需注意奥希替尼可在用药数天至数月后引起心力衰竭。更多还原

【Abstract】 Objective To analyze the clinical characteristics and potential mechanisms of heart failure caused by osimertinib mesylate tablets(osimertinib) in order to provide a reference for safe use of osimertinib and for clinical management. Methods The clinical data of a 59-year-old patient with lung adenocarcinoma who developed heart failure after taking osimertinib was analyzed. Combined with related literature, the Naranjo’s score was used to find out about the drugs that might have caused heart failure, causes of occurrence, and measures for prevention and treatment. Results It was very likely that osimertinib caused heart failure in this patient. After discontinuation of osimertinib and management of heart failure, the patient’s cardiac function significantly improved. Conclusion Despite the scarcity of cases of heart failure caused by osimertinib, clinicians should be aware that osimertinib can cause heart failure a few days to several months after administration.更多还原